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ABSTRACT
Objectives: To argue that discrete event simulation should be preferred to
cohort Markov models for economic evaluations in health care.
Methods: The basis for the modeling techniques is reviewed. For many
health-care decisions, existing data are insufﬁcient to fully inform them,
necessitating the use of modeling to estimate the consequences that are
relevant to decision-makers. These models must reﬂect what is known
about the problem at a level of detail sufﬁcient to inform the questions.
Oversimpliﬁcation will result in estimates that are not only inaccurate, but
potentially misleading.
Results: Markov cohort models, though currently popular, have so many
limitations and inherent assumptions that they are inadequate to inform
most health-care decisions. An event-based individual simulation offers an
alternative much better suited to the problem. A properly designed discrete
event simulation provides more accurate, relevant estimates without being
computationally prohibitive. It does require more data and may be a
challenge to convey transparently, but these are necessary trade-offs to
provide meaningful and valid results.
Conclusion: In our opinion, discrete event simulation should be the pre-
ferred technique for health economic evaluations today.
Keywords: decision tree, discrete event simulation, economic evaluation,
Markov, modeling.
Introduction
Despite enormous investments in research on the effects of new
health technologies, the resulting data will almost always be
insufﬁcient to inform health-care decisions. Information coming
from clinical trials may have strong internal validity, but it will
suffer from poor applicability to the messier world of actual
practice. Moreover, it will tend to be short term and cover only
an extremely limited range of available options. Cost data from
clinical trials are even less usable in most cases because the study
environment so modiﬁes practice that the resulting resource use
is a poor reﬂection of reality. These data are unlikely to be
speciﬁc or adequately transferable to a particular country and, in
any case, will not provide information on the longer-term con-
sequences of adopting the new technology [1,2]. Indeed, eco-
nomic data from clinical trials may not be available at all. Thus,
modeling of the economic outcomes is an essential component of
the evaluations [3].
Models inform decisions when relevant, real-world data are
not yet available [4]. They can be used to test a wide range of
scenarios and strategies to identify the most efﬁcient and equi-
table allocation of resources and allow extrapolation to other
countries or regions and other populations. To be useful tools,
models must reﬂect reasonably well what is understood about the
illness and its management that is relevant to the problem at
hand. This face validity requires that the chosen technique be
able to include all the pertinent components and that it be
capable of handling the known relationships in the data accu-
rately. Although models always involve some simpliﬁcation of
reality, it is important that these assumptions not distort the
picture to the extent that the result is misinformation [5].
In this article, we argue that discrete event simulation is the
preferred modeling technique for health economic evaluations, if
these are to be sufﬁciently accurate to be taken seriously when
informing health-care decisions, and that this must take prece-
dence over familiarity and the ease of conveying the methods. It
is also argued that the prevailing Markov approach is rarely
adequate for this purpose.
Elements of the Choice
Modeling techniques can be characterized according to many
features [6,7], but two particularly important ones for deﬁning
the choice for health economic evaluations are the nature of the
object that is modeled and the basis for conceptualizing what
happens to those objects. The basic options for objects are to
model a population as a whole (often referred to as cohort or
aggregate modeling) or to model the individuals in the popula-
tion (also known as patient-level simulation). The main alterna-
tive conceptualizations are to represent the problem as a series of
states that the objects can be in or to think instead of the events
the objects can experience. Multiple variations of these
approaches exist, including hybrids, but it is common practice in
health economics today to use a cohort, state-transition
technique—the typical Markov model. By contrast, an event-
driven individual method—discrete event simulation—has been
proposed as a better choice [8].
Cohort versus Individual
There are two major problems with a cohort approach, both
readily illustrated with the simplest of examples. Suppose we are
evaluating a treatment that prevents the transition from being
healthy to being sick—for example, having a myocardial infarc-
tion. In the cohort approach, the entire population is healthy at
the start; and after a given time period, some proportion will
have had the myocardial infarction (Fig. 1).
One major problem is in determining that proportion at each
relevant time point. That proportion is given by the risk the
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population is exposed to more than a given period, and that risk
is affected, presumably, by treatment. It is not only treatment that
modiﬁes the risk, however. It will also depend on patient char-
acteristics, such as age, sex, smoking, and other risk factors. That
is why we are interested in characterizing the population and
examining these factors. So the risk depends on the characteris-
tics of the population, but how do we express these and compute
the transition probability? The common approach of using the
“mean” proﬁle given by the average value of each characteristic
will not yield the correct answer because the factors never dis-
tribute perfectly normally with no correlations among them. But
there is an even bigger problem in determining the proportion.
The ﬂow out of healthy to sick is not random: It is the higher-risk
people who tend to move out earlier—the older ones, those who
smoke, and so on. This phenomenon, known in epidemiology as
depletion of susceptibles [9], means that characterizing the
cohort population over time becomes extremely difﬁcult because
the distributions of risk factors are being altered by the transi-
tions. The typical approach today ignores this and simply adds
the cycle time to the age, assumes the proportions of males and
smokers are constant, and so on. This is incorrect (Fig. 2) and
will yield inaccurate results.
A similar problem occurs with the portion of the cohort
that has become sick. It is very difﬁcult to characterize these
patients in terms of features that may be determinants of
further risk, mortality, quality of life, resource use, and other
elements relevant to the model because the arriving fractions
mix into the ones already there. Thus, it is difﬁcult to accu-
rately estimate these important items. By the same token, if any
of them depend on the duration of illness (for example, how
long it has been since the myocardial infarction occurred), the
estimates will be inaccurate given that the arriving portions mix
into a single group and do not retain any “memory” of when
they became sick.
An attempt at solving these problems is to deﬁne the cohort as
homogeneous—for example, only 65-year-old male smokers.
Given that everyone in the population is the same in terms of the
modeled risk factors, it is hoped that the issue goes away. For
most applications, however, the number of homogeneous popu-
lations required to reasonably reﬂect the proﬁles deﬁned by com-
binations of modeled risk factors would be vast, forcing the
analyst to limit these to a feasible few. Even then, the depletion of
susceptibles still occurs, and use of a constant probability would
be inappropriate.
A solution to the problem of losing memory of the time when
sickness started is to keep the arriving subgroups separate
according to the time the sickness started (so-called “tunnel
states” [7]), but this greatly increases complexity and is only
feasible for a very limited number of items that need to be
remembered [10].
The second major problem with the cohort approach is in the
application of competing risks over time. If we add another
condition to our example, say, death (Fig. 3), then at each cycle
one must determine the proportion of the population transition-
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Figure 1 Cohort representation of an extremely simple model. The pie charts
are snap shots of the population at various times.
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Figure 2 Depletion of susceptibles.At year 0, the cohort consists of 75% male, 30% smokers, with a mean age of 55 years.These factors are all part of the risk
equation for the transition to sick.The graph shows the actual mean values of the remaining healthy portion of the cohort at each time point. Note: after 3 years,
the depletion changes the pattern so that the age mean is affected in a much lower grade than previous years.
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ing to each of the conditions. These proportions are given by the
underlying risks, which “compete” in the sense that people in the
population are vulnerable to all of them simultaneously. This
competition means that some people will not be affected by one
risk because the other one “got them” ﬁrst—people who die are
no longer exposed to the risk of myocardial infarction, for
example. So the population will manifest a lower probability
than would be the case if it was subject to only the risk of
myocardial infarction, but deriving that value is very difﬁcult, as
has long been recognized in epidemiology and biostatistics.
All the serious problems with the cohort approach are readily
solved by modeling individuals instead of the entire population in
the aggregate. For each individual (known as entities in discrete
event simulation), the risk can be computed based on their char-
acteristics, the values of these factors can be easily updated over
time as appropriate, the risks can be recalculated when necessary,
and any number of competing risks can be correctly applied by
deriving the implied time to each event. Individuals can face any
number of risks simultaneously. When an event happens, their
characteristics can be updated without problem. If there are time
dependencies, these can be considered, and of course, what hap-
pened before can be remembered and used appropriately. There
is no need to work at the mean or restrict the analyses to
homogeneous populations or to deploy any of the variety of
work-arounds, such as applying one risk before the other or
randomly ordering the risks, common in today’s Markov models.
To be sure, individual modeling requires more calculations and is
somewhat more difﬁcult to implement, especially if the imple-
mentation is required to be in a spreadsheet, but cohort models
will not produce accurate estimates and will force untenable
assumptions. Choosing a cohort approach would only be appro-
priate if population characteristics do not affect transition prob-
abilities, there are no competing risks, and there is no need to
reﬂect dependence on time or prior history and other such fea-
tures of the course of illness. Clearly, these conditions never hold
in health economic evaluations.
State versus Event
In a state-transition model, the world is conceptualized as a series
of snapshots of the states that the population may be in. These
snapshots occur at ﬁxed, discrete time points called cycles. Thus,
in our simple example, there would be two states—one for
healthy and one for sick—and a third state for dead (Fig. 3). The
myocardial infarction would be the transition from healthy to
sick, and the model would derive the distribution of the popula-
tion into these three states after each cycle.
This is an awkward way to conceptualize medical conditions
because they tend not to fall into discrete states, especially ones
that must be mutually exclusive. Trying to represent the condi-
tion in this way leads to either a vast number of states (in our
simple problem, one would have to consider things like diabetes,
hypertension, smoking, hypercholesterolemia, and so on) corre-
sponding to all the possible combinations or to inaccuracies
resulting from the required simpliﬁcation. Moreover, at least as
commonly implemented in health economics, the snapshots are
taken at ﬁxed, discrete intervals, and only one transition is
allowed in between—both limitations that lead to further
inaccuracy.
Not only does the state approach lead to considerable unnec-
essary complexity, it also leaves no room for important elements
of the problem that cannot be represented as states. For example,
the physician may make several decisions when the patient
suffers a myocardial infarction, and even beforehand, treatment
may be altered according to results of tests and the patient’s
experience. Occurrence of the infarction can lead to an emer-
gency room visit where a series of actions take place, perhaps
culminating in hospitalization. Depending on what is happening,
various risks, including that of death, may be changing. There is
no clear way to represent any of this in a state-transition model.
It is much more natural to conceptualize the world in terms of
the events that can happen. By thinking in terms of events rather
than states, the problems are solved. It is very easy to design the
model in terms of what can happen. The myocardial infarction is
an obvious event, but so to is the visit to the doctor where various
tests happen, decisions are taken, and treatment is altered.
Arrival in the emergency visit and any number of actions taken
there including hospitalization, and of course, at any point, death
is similarly of the event form. The resulting design is much more
compact and transparent, yet of greatly increased accuracy, than
any comparable state-based design. Indeed, it is difﬁcult to think
of any reason, other than familiarity with the prevalent
approach, for choosing a state-based representation. The original
one, having to do with the easy mathematical solution to a
matrix reﬂecting the Markov chain transitions, does not hold in
the vast majority of situations faced in health economics.
Discrete Event Simulation versus
Markov Model
In a discrete event simulation, the experience of individuals is
modeled over time in terms of the events that occur and the
consequences of those events. This approach is far preferable to
the typical Markov one, which tries to shoehorn the world into
a series of states more than which a cohort is successively dis-
tributed. All of the many limitations and inaccuracies of Markov
models are easily avoided with discrete event simulation. There
are some problems that arise, however.
Modeling at the individual level requires a much greater
number of calculations. This is rarely a problem with the com-
puting power readily available in laptops today, provided that
two aspects are attended to. One is that the model should not be
forced to process one individual at a time. Doing so is very
inefﬁcient because much of the time nothing relevant is happen-
ing to that individual, yet the model has to process the entity
anyway. This problem is compounded if the simulation is set up
to consider only one time unit (for example, a day) at a time.
Instead, the model can and should be allowed to consider many
individuals simultaneously. This allows the model to efﬁciently
process events as they happen throughout the population and
Figure 3 Competing risks.Which risk should the patient be exposed to ﬁrst?
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substantially reduces the number of calculations, particularly if
time is permitted to jump to the occurrence of the next event
rather than proceed in ﬁxed, even units.
The other aspect that needs to be taken care of to reduce the
number of calculations has to do with the stochastic nature of
individual simulations. In order to represent the varying experi-
ences of individuals and apply the various risks, decisions,
resource use, and other elements that are variable, the models use
random numbers (for example, if 10% of patients with myocar-
dial infarction are discharged home from the emergency room,
then a number drawn randomly between zero and one will
indicate discharge if it is below 0.1). As with any stochastic
process, accurate representation requires enough draws to prop-
erly reﬂect the variability, and this implies that the more variabil-
ity, the higher the number of draws. In a simulation, this
translates to requiring added numbers of individuals to be
modeled and thus many more calculations. Lessening this burden
is a matter of reducing the nuisance variance, and various tech-
niques, including cloning the individuals, exist to accomplish this
[11,12]. When these aspects are addressed, simulations run very
efﬁciently, and it is not a problem to carry out probabilistic or
other sensitivity analyses [11].
The quality of models also hinges on the supporting
data—the larger the gaps, the less certain in the estimates pro-
duced by the model. To be sure, a reasonably informative discrete
event simulation requires more detailed data than a typical
Markov cohort model. Nevertheless, as the paper reporting on
discrete event simulation of glaucoma treatments [13] points out,
the data required to inform an individual Markov model that
would approach the level of accuracy of a discrete event simula-
tion are just as burdensome. In fact, ﬁtting the state transition
framework can require more calculations and processing than a
discrete event simulation where events can be predicted by mul-
tivariate time-to-event functions. Furthermore, the position that
lack of readily available data justiﬁes a simple cohort model is
untenable when the purpose is informing real health-care deci-
sions. An inaccurate model is not preferable to nothing and
should become an increasingly unacceptable approach as
decision-makers demand appropriate estimates. We have found
that in most cases, the data are available, though greater efforts
may be required to acquire and analyze them so they can inform
a discrete event simulation.
If data are truly limited, a discrete event simulation provides
a substantial advantage because the inadequacy of the data is not
built into the structure of the model. The simulation can be
designed to properly reﬂect the problem and carry out explor-
atory analyses with the limited data and best guesses; it can then
incorporate additional data should these become available. A
cohort Markov model that only applies an average treatment
effect to the risk given by a mean patient proﬁle cannot, for
example, be easily modiﬁed to account for compliance that is
affected by patient characteristics and treatment response. Such
an addition would force a complete reprogramming of the
model. In a discrete event simulation, compliance can be built in
from the outset (or, with a small effort, added at a later stage),
and when data become available, it is relatively straightforward
to incorporate treatment- and patient-speciﬁc effects.
Like most computer-intensive activities, building a discrete
event simulation is best done using appropriate software.
Although it is possible to construct one using spreadsheets, this is
not a good choice because their “calculate everything every time”
nature is precisely the opposite of the required “calculate sequen-
tially and only when relevant.” Moreover, structuring the simu-
lation and displaying it transparently is difﬁcult to do with
spreadsheets. Software designed for decision trees is not much
better. Although linear programming languages, such as C++ can
be used, they too present drawbacks in terms of transparency and
the degree of programming skills required. Fortunately, there is
abundant software speciﬁcally designed for discrete event simu-
lation that that greatly facilitates the development of these
models, their efﬁcient calculation, and transparent presentation.
Of these, ARENA (Rockwell Automation, Warrendale, PA) is the
most widely used. The main limitation of these packages is that
they are not designed for health-care decision problems and,
thus, require the modeler to adapt tools and concepts from other
ﬁelds. The specialized software is also much more expensive than
typical spreadsheet software.
This brings us to perhaps the greatest challenge faced by
discrete event simulation in our ﬁeld today: the familiarity of
analysts throughout academia, regulatory agencies, and the
private sector with cohort Markov models. It is understandable
that when faced with the need to develop, assess, or use complex
models, there is a reluctance to step out of the comfort zone and
enter unfamiliar territory. Hopefully, as the severe limitations of
the cohort Markov technique become more evident, those who
must have the expertise to develop reliable and valid models or to
evaluate them will adopt the much better discrete event simula-
tion approach and help educate nontechnical audiences on the
need for this more advanced modeling technique.
Transparency
The authors of the article on discrete event simulation of glau-
coma treatments [13] ably demonstrate the advantages of this
approach but lament that it is difﬁcult to convey transparently.
Nevertheless, they have included an appendix where they have
been able to provide a concise and understandable description of
the model and data sources and a full technical description of the
data and methods. Although the technical appendix may seem
lengthy, a full description of any reasonably accurate model
requires this level of detail. Journals willing to include the tech-
nical details behind models enable transparency, and with the
option to post these online, space restrictions should no longer be
a limiting. Indeed, such appendices should be the norm, rather
than the exception.
That said, it may not be the lengthy reporting that some may
view as inhibiting transparency, but rather the sophisticated cal-
culations underlying the model and the number of relationships
considered. This can, indeed, be a challenge to convey, and even
more to review competently; but if it is the level of detail required
to adequately represent the problem, then this needs trumps any
transparency issues [5]. Moreover, as the glaucoma researchers
point out [13], the transition matrices required to approach the
level of detail necessary for their analysis would have been pro-
hibitive. A model based on thousands of transition matrices,
countless tunnel states, and hundreds of disease states would be
enormously difﬁcult to navigate, and certainly not any more
transparent, particularly if programmed using spreadsheets, than
a discrete event simulation.
The complexity of the equations underlying the model calcu-
lations is another matter. It is undoubtedly true that an acceler-
ated Weibull function is more difﬁcult to understand than a
simple constant probability. It is easier to describe the “average
patient” and an “average treatment effect” than it is to explain
the correlations required to properly simulate multiple individual
characteristics and how these relate to risk and treatment effect.
Again, accuracy must outweigh transparency, especially for those
without the background to evaluate the mathematics underlying
the model. Decision-makers must ensure availability of the exper-
tise capable of evaluating accurate simulations, rather than
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insisting on simplicity for its own sake, even it leads to unreliable
models.
Conclusion
It is remarkable that an article arguing that discrete event simu-
lation should be preferred more than Markov models is still
required, given that in all other ﬁelds of human endeavor the
techniques described here are commonplace and taken to be the
standard [14]. Although several publications have proposed
guidelines for choosing a modeling technique, we do not believe
there is any substantive basis for selecting a cohort Markov
approach to inform health care decisions. Our ﬁeld would do
well to relinquish its commitment to this rudimentary technique
and focus instead on gaining experience with discrete event simu-
lation, or indeed other more appropriate techniques such as
agent-based simulation or dynamic transmission models, in order
to supply decision-makers with models that are sufﬁciently accu-
rate to provide credible information.
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